论文部分内容阅读
目的观察大功率微波热疗联合希罗达、奥沙利铂治疗晚期胃癌近期疗效及副作用。方法共收录晚期胃癌患者28例,其中男15例,女13例,年龄35～68岁,平均年龄48.6岁。28例均为晚期胃癌,所有病例中24例有病理证实,并有明确的可测病灶。4例无病理证实,但有明确可测病灶。卡氏评分≥40分,预计生存期≥3个月,既往化疗18例,其中有8例含有奥沙利铂,所有病例均未应用希罗达化疗。化疗前查血常规、肝肾功能均正常,并均征求患者同意。结果每例患者完成3～4周期化疗后评价。5例达CR,11例达PR,9例达SD,3例达PD,有效率(CR+PR)达57.1%,中位缓解期10月,中位生存期13.2月。毒副反应主要表现为胃肠道毒性、血液毒性、外周神经毒性及手足综合征,且均为Ⅰ～Ⅱ度,对治疗无影响;大功率微波热疗治疗后部分病例不同程度出现局部皮肤红肿,次日均恢复正常,不影响治疗。结论大功率微波热疗联合希罗达、奥沙利铂治疗晚期胃癌疗效较好,耐受力好,无严重不良副反应,适用于临床治疗。
Objective To observe the short-term curative effect and side effects of high-power microwave hyperthermia combined with Xeloda and Oxaliplatin in the treatment of advanced gastric cancer. Methods A total of 28 patients with advanced gastric cancer were enrolled, including 15 males and 13 females, aged 35-68 years, with an average age of 48.6 years. Twenty-eight cases were all advanced gastric cancer. Twenty-four cases were pathologically confirmed with definite measurable lesions. 4 cases without pathology confirmed, but there is a clear measurable lesions. Card score ≥ 40 points, the expected survival of ≥ 3 months, 18 cases of previous chemotherapy, of which 8 cases contain oxaliplatin, no case of Xeloda chemotherapy. Check blood before chemotherapy, liver and kidney function are normal, and seek patient consent. Results Each patient completed 3 to 4 cycles of chemotherapy after the evaluation. 5 were CR, 11 were PR, 9 were SD, 3 were PD. The effective rate (CR + PR) was 57.1%. The median remission was 10 months and the median survival was 13.2 months. Toxic and side effects mainly manifested as gastrointestinal toxicity, hematotoxicity, peripheral neurotoxicity and hand-foot syndrome, and are Ⅰ ~ Ⅱ degree, no effect on the treatment; high-power microwave hyperthermia in some cases of local skin swelling to varying degrees , The next day were back to normal, does not affect the treatment. Conclusion High-power microwave hyperthermia combined with Xeloda, oxaliplatin treatment of advanced gastric cancer better efficacy, good tolerance, no serious side effects, suitable for clinical treatment.